S1916 Digital Medicine Program for Pain Control in Cancer Patients
Status:
Terminated
Trial end date:
2020-09-16
Target enrollment:
Participant gender:
Summary
This is a feasibility study to assess the use of a Digital Medicine Program (consisting of an
FDA-approved ingestible sensor co-encapsulated with oxycodone/acetaminophen (5 mg/325 mg), a
small wearable patch, and a mobile application) in cancer patients with metastatic disease
experiencing uncontrolled pain.
Phase:
N/A
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
Proteus Digital Health, Inc.
Treatments:
Acetaminophen Acetaminophen, hydrocodone drug combination Oxycodone